Novo Nordisk B A/S
Novo Nordisk B A/S
1.01 %
301.50 DKK
3.00
Quote
301.50
High
302.60
Change
1.01 %
Low
299.30
Updated
21/09/2018
Open
300.00
News about Novo Nordisk B A/S
Factsheet for Novo Nordisk B A/S
Company Profile
Description
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, as well as oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Key Stats
Website: http://www.novonordisk.com
Headquarter country: Denmark
Employees: 35,000
Market Cap (at close 21/09/2018): DKK 719B
Fiscal Year Ends: December
Stats

Stats 2017 2016 2015 2014 2013
Price/Earnings 21.60 17.30 31.30 26.50 21.60
Forward Price/Earnings 20.20 16.20 25.60 23.00 18.70
Price/Free Cash Flow 21.90 16.80 33.80 26.40 29.70
Return on Assets 38.20 40.10 41.30 35.90 37.00
Return on Equity 80.20 82.20 79.90 63.90 60.50
Return on Invested Capital 78.60 81.10 78.30 63.10 60.00
Dividend


Dividend/Share:7.60
Ex. Dividend Date:31/12/2017
Trailing Dividend Yield:2.63
Payout Ratio:49.12
Date Currency Amount
31/03/2018 DKK 4.85
30/09/2017 DKK 3.00
31/03/2017 DKK 4.60
30/09/2016 DKK 3.00
31/03/2016 DKK 6.40
31/03/2015 DKK 5.00
Income Statement

Revenue 2017 2016 2015 2014 2013
Total Revenue 111,696 111,780 107,927 88,806 83,572
Gross Profit 94.06 94.60 91.74 74.24 69.43
Gross Margin % 84.21% 84.63% 85.00% 83.60% 83.08%
Operating Expenses 2017 2016 2015 2014 2013
EBITDA 51,952 51,056 46,509 37,570 35,393
Net income 38,130 37,925 34,860 26,481 25,184
Basic Earnings Per Share 15.42 14.99 13.56 10.10 9.40
Operating Income 48.97 48.43 49.44 34.49 31.49
Operating Margin % 43.84% 43.33% 45.81% 38.84% 37.68%
Cash Flow

Cash Flow 2017 2016 2015 2014 2013
Operating Cash Flow 41,168 48,314 38,287 31,692 25,942
Capital Expenditures -8,648.00 -8,267.00 -6,406.00 -4,335.00 -3,644.00
Free Cash Flow 32,520 40,047 31,881 27,357 22,298
Balance Sheet

Assets 31/12/2017 31/12/2016 31/12/2015 31/12/2014 31/12/2013
Current Assets 60,080,000 59,766,000 55,140,000 46,293,000 42,058,000
Long Term Assets 42,275,000 37,773,000 36,659,000 30,769,000 28,279,000
Total Assets 102,355,000 97,539,000 91,799,000 77,062,000 70,337,000
Liabilities 31/12/2017 31/12/2016 31/12/2015 31/12/2014 31/12/2013
Total Current Liabilities 47,056,000 47,436,000 40,873,000 33,689,000 24,225,000
Long Term Liabilities 4,834,000 3,957,000
Total Liabilities 52,270,000 44,830,000
Equity 31/12/2017 31/12/2016 31/12/2015 31/12/2014 31/12/2013
Retained Earnings 48,977,000 46,111,000 46,816,000 41,277,000 41,137,000
Treasury Stock 11,000 9,000.00 10,000 11,000 21,000
Total Stockholder Equity 49,815,000 45,269,000 46,969,000 40,294,000 42,569,000
Net Tangible Assets 46,490,000 42,555,000 44,811,000 38,916,000 40,954,000